Consent and long-term neuroleptic treatment.
The involvement of clients in the process of developing their care and treatment package is well established. If a genuine collaboration in treatment is achieved one of the fundamental bases of this process lies with 'informed consent'. Neuroleptic medication forms the basis of relapse prevention treatment for people suffering from schizophrenia with non-adherence to treatment seen as the largest cause of relapse. This paper reviews the complex and difficult issues in obtaining informed consent for this client group from within the context of the nurse's role and the problems that arise as a consequence of the blurring of professional boundaries. Throughout the paper reference is made to the expectations made by the UKCC, which provides clarification of nurses' practice in this area.
Harris
N R
NR
School of Nursing, Midwifery and Health Visiting, University of Manchester, Manchester, UK.
Lovell
K
K
Day
J C
JC
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D006801:Humans; D007258:Informed Consent; D024802:Nurse's Role; D012559:Schizophrenia / Q000188:drug therapy* / Q000451:nursing*; D013997:Time Factors
D014150:Antipsychotic Agents